BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

NCT06608940 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding unavailable

Conditions

Hepato Cellular Carcinoma (HCC)

Interventions

DRUG: BC3402
DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Case Comprehensive Cancer Center